Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20060) 20060
Book Chapter (235) 235
Publication (46) 46
Dissertation (34) 34
Newspaper Article (34) 34
Magazine Article (31) 31
Conference Proceeding (24) 24
Web Resource (10) 10
Book / eBook (3) 3
Book Review (2) 2
Reference (2) 2
Streaming Video (2) 2
Trade Publication Article (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (17982) 17982
humans (14558) 14558
science & technology (13411) 13411
life sciences & biomedicine (13168) 13168
female (7553) 7553
male (7356) 7356
middle aged (6151) 6151
antibodies, monoclonal, murine-derived (5163) 5163
adult (5094) 5094
aged (4710) 4710
treatment outcome (4403) 4403
hematology (4067) 4067
antibodies, monoclonal - therapeutic use (3900) 3900
oncology (3715) 3715
antineoplastic combined chemotherapy protocols - therapeutic use (2994) 2994
antibodies, monoclonal, murine-derived - therapeutic use (2841) 2841
biological and medical sciences (2815) 2815
medical sciences (2790) 2790
lymphoma (2191) 2191
antineoplastic agents - therapeutic use (2175) 2175
rituximab - therapeutic use (2151) 2151
immunologic factors - therapeutic use (2052) 2052
aged, 80 and over (1837) 1837
rheumatology (1794) 1794
care and treatment (1728) 1728
chemotherapy (1718) 1718
patients (1712) 1712
retrospective studies (1698) 1698
antibodies, monoclonal - administration & dosage (1677) 1677
antibodies, monoclonal, murine-derived - administration & dosage (1667) 1667
cyclophosphamide - administration & dosage (1574) 1574
prognosis (1560) 1560
immunology (1531) 1531
abridged index medicus (1525) 1525
lymphomas (1484) 1484
antineoplastic agents (1482) 1482
immunosuppressive agents - therapeutic use (1481) 1481
cancer (1454) 1454
hematologic and hematopoietic diseases (1424) 1424
adolescent (1394) 1394
medicine & public health (1389) 1389
young adult (1373) 1373
lymphoma, large b-cell, diffuse - drug therapy (1349) 1349
transplantation (1339) 1339
immunotherapy (1337) 1337
remission induction (1287) 1287
antineoplastic combined chemotherapy protocols - administration & dosage (1257) 1257
rituximab - administration & dosage (1204) 1204
hemic and lymphatic diseases (1196) 1196
vincristine - administration & dosage (1192) 1192
cyclophosphamide (1185) 1185
rheumatoid arthritis (1181) 1181
recurrence (1167) 1167
monoclonal antibodies (1153) 1153
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (1143) 1143
doxorubicin - administration & dosage (1119) 1119
drug therapy (1103) 1103
follow-up studies (1092) 1092
disease-free survival (1085) 1085
cyclophosphamide - therapeutic use (1080) 1080
animals (1065) 1065
general & internal medicine (1059) 1059
prednisone - administration & dosage (1036) 1036
medicine, general & internal (1023) 1023
antibodies, monoclonal - adverse effects (1012) 1012
risk factors (1006) 1006
lymphocytes b (980) 980
analysis (964) 964
antimitotic agents (950) 950
antirheumatic agents - therapeutic use (948) 948
antibodies, monoclonal, murine-derived - adverse effects (928) 928
pharmacology. drug treatments (927) 927
b-lymphocytes - immunology (915) 915
antigens, cd20 - immunology (882) 882
drug therapy, combination (875) 875
health aspects (869) 869
child (863) 863
lymphoma, b-cell - drug therapy (862) 862
immune system diseases (853) 853
antineoplastic combined chemotherapy protocols - adverse effects (841) 841
combined modality therapy (834) 834
research (828) 828
time factors (817) 817
arthritis, rheumatoid - drug therapy (804) 804
lymphoma, non-hodgkin - drug therapy (796) 796
leukemia, lymphocytic, chronic, b-cell - drug therapy (787) 787
clinical trials (763) 763
antineoplastic agents - administration & dosage (729) 729
pharmacology & pharmacy (728) 728
prednisone - therapeutic use (727) 727
immunoglobulins (725) 725
tumors (715) 715
biopsy (709) 709
antibodies (694) 694
neurosciences & neurology (681) 681
lymphoma, follicular - drug therapy (676) 676
pediatrics (667) 667
lymphoma, large b-cell, diffuse - pathology (658) 658
b-lymphocytes - drug effects (655) 655
drug administration schedule (655) 655
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18575) 18575
Japanese (484) 484
French (480) 480
Spanish (350) 350
German (329) 329
Chinese (239) 239
Russian (160) 160
Polish (82) 82
Portuguese (82) 82
Korean (75) 75
Czech (69) 69
Italian (68) 68
Hungarian (44) 44
Turkish (22) 22
Danish (17) 17
Croatian (16) 16
Norwegian (11) 11
Dutch (10) 10
Hebrew (10) 10
Finnish (7) 7
Slovak (5) 5
Swedish (5) 5
Icelandic (3) 3
Serbian (3) 3
Indonesian (2) 2
Persian (2) 2
Romanian (2) 2
Slovenian (2) 2
Belarusian (1) 1
Bosnian (1) 1
Catalan (1) 1
Estonian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rituximab bei therapierefraktärem, generalisierten Lupus erythematodes tumidus
by Alexander Kreuter and Christian Tigges and Nicolas Hunzelmann and Frank Oellig and Percy Lehmann and Silke C Hofmann
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 07/2017, Volume 15, Issue 7, p. 729
Rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
by Morschhauser, Franck and Fowler, Nathan H and Feugier, Pierre and Bouabdallah, Kamal and Bouabdallah, Reda and Tilly, Hervé and Palomba, M. Lia and Fruchart, Christophe and Libby, Edward N and Casasnovas, Rene-Olivier and Flinn, Ian W and Haioun, Corinne and Maisonneuve, Hervé and Ysebaert, Loic and Bartlett, Nancy L and Brice, Pauline and Ribrag, Vincent and Daguindau, Nicolas and Le Gouill, Steven and Pica, Gian M and Martin Garcia-Sancho, Alejandro and López-Guillermo, Armando and Larouche, Jean-François and Ando, Kiyoshi and Gomes da Silva, Maria and André, Marc and Zachée, Pierre and Sehn, Laurie H and Tobinai, Kensei and Cartron, Guillaume and Liu, David and Wang, Jianming and Xerri, Luc and Salles, Gilles A and RELEVANCE Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 10, pp. 934 - 947
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thalidomide - adverse effects | Skin Diseases - chemically induced | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Follicular - mortality | Male | Survival Rate | Thalidomide - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Neutropenia - chemically induced | Rituximab - adverse effects | Chemotherapy | Usage | Lymphomas | Drug therapy | Cancer | Fees & charges | Lymphocytes B | Immunomodulation | Immunotherapy | Advisors | Rituximab | Clinical medicine | Patients | Lymphoma | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL
by Awasthi, Aradhana and Ayello, Janet and Van de Ven, Carmella and Elmacken, Mona and Sabulski, Anthony and Barth, Matthew J and Czuczman, Myron S and Islam, Humayun and Klein, Christian and Cairo, Mitchell S
British journal of haematology, ISSN 0007-1048, 12/2015, Volume 171, Issue 5, pp. 763 - 775
rituximab‐sensitive BL | rituximab‐resistant BL | pre‐B‐ALL | obinutuzumab | rituximab | Rituximab | Obinutuzumab | Pre-B-ALL | Rituximab-sensitive BL | Rituximab-resistant BL | Life Sciences & Biomedicine | Hematology | Science & Technology | Neoplasm Transplantation | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Rituximab - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Caspases - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Survival Analysis | Cell Line, Tumor | Caspases - drug effects | Lysosomal-Associated Membrane Protein 1 - metabolism | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Interferon-gamma - biosynthesis | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | Cell death | Patient outcomes | Monoclonal antibodies | Biochemistry | Comparative analysis | Antineoplastic agents | Burkitt's lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
by Salles, Gilles and Barrett, Martin and Foà, Robin and Maurer, Joerg and O’Brien, Susan and Valente, Nancy and Wenger, Michael and Maloney, David G
Advances in therapy, ISSN 0741-238X, 10/2017, Volume 34, Issue 10, pp. 2232 - 2273
CD20 | Treatment outcome | Rheumatology | Rituximab | Internal Medicine | Oncology | Monoclonal antibody | Diffuse large B-cell lymphoma | Non-Hodgkin lymphoma | Chronic lymphocytic leukemia | Medicine & Public Health | Follicular lymphoma | Safety | Cardiology | Pharmacology/Toxicology | Endocrinology | B-cell lymphoma | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | History, 21st Century | History, 20th Century | Humans | Antineoplastic Agents, Immunological - history | Rituximab - pharmacology | B-Lymphocytes - drug effects | Rituximab - therapeutic use | Animals | Antineoplastic Agents, Immunological - therapeutic use | Hematologic Neoplasms - drug therapy | Rituximab - history | Lymphoma, B-Cell - history | Hematologic Neoplasms - history | Lymphoma, B-Cell - drug therapy | Development and progression | Lymphomas | Drug approval | Leukemia | Health technology assessment | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text 292 Switching to biosimilar rituximab: a real world study
by Nisar, Muhammad K
Rheumatology (Oxford, England), ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Rituximab for the treatment of 15 patients with recurrent type 1 autoimmune pancreatitis
by De Marchi, Giulia and Vieceli, Filippo and Amodio, Antonio and Davì, Valeria and Conti Bellocchi, Maria Cristina and Campagnola, Pietro and Bernardoni, Laura and Crinò, Stefano Francesco and Gabbrielli, Armando and Ciccocioppo, Rachele and Frulloni, Luca
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], ISSN 1424-3903, 06/2019, Volume 19, pp. S50 - S50
Rituximab | Pancreatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Preparation & in vitro evaluation of 90Y-DOTA-rituximab
by Kameswaran, Mythili and Pandey, Usha and Dash, Ashutosh and Samuel, Grace and Venkatesh, Meera
Indian journal of medical research (New Delhi, India : 1994), ISSN 0971-5916, 01/2016, Volume 143, Issue JANUARY, pp. 57 - 65
Rituximab | Non-hodgkin’s lymphoma | 0y-dota-rituximab | Radioimmunotherapy | Lymphoma, Non-Hodgkin - immunology | Radiopharmaceuticals - chemistry | Rituximab - pharmacokinetics | Heterocyclic Compounds - administration & dosage | Humans | Organometallic Compounds - pharmacokinetics | Lymphoma, Non-Hodgkin - pathology | Radiopharmaceuticals - administration & dosage | Rituximab - administration & dosage | Tissue Distribution | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds - chemistry | Cell Line, Tumor | Radioimmunotherapy - methods | Heterocyclic Compounds - pharmacokinetics | Organometallic Compounds - chemistry | Mice | Rituximab - chemistry | Lymphoma, Non-Hodgkin - drug therapy | Organometallic Compounds - administration & dosage | Index Medicus | radioimmunotherapy | Non-Hodgkin's lymphoma | Original | rituximab | 90Y-DOTA-rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Rituximab‐induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti‐rituximab antibodies
by Vendramin, Chiara and Thomas, Mari and Westwood, John‐Paul and McGuckin, Siobhan and Scully, Marie
British journal of haematology, ISSN 0007-1048, 03/2019, Volume 184, Issue 5, pp. 858 - 861
rituximab: serum sickness | antibodies to rituximab | thrombotic thrombocytopenic purpura | adverse drug reaction | Life Sciences & Biomedicine | Hematology | Science & Technology | Rituximab - administration & dosage | Serum Sickness - chemically induced | Humans | Middle Aged | Purpura, Thrombotic Thrombocytopenic - drug therapy | Adult | Antibodies - blood | Female | Purpura, Thrombotic Thrombocytopenic - blood | Rituximab - adverse effects | Serum Sickness - blood | Thrombocytopenic purpura | Biological products | Antibodies | Rituximab | Thrombotic thrombocytopenic purpura | Purpura | Serum sickness | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
by Charles, Pierre and Terrier, Benjamin and Perrodeau, Élodie and Cohen, Pascal and Faguer, Stanislas and Huart, Antoine and Hamidou, Mohamed and Agard, Christian and Bonnotte, Bernard and Samson, Maxime and Karras, Alexandre and Jourde-Chiche, Noémie and Lifermann, François and Gobert, Pierre and Hanrotel-Saliou, Catherine and Godmer, Pascal and Martin-Silva, Nicolas and Pugnet, Grégory and Matignon, Marie and Aumaitre, Olivier and Viallard, Jean-François and Maurier, François and Meaux-Ruault, Nadine and Rivière, Sophie and Sibilia, Jean and Puéchal, Xavier and Ravaud, Philippe and Mouthon, Luc and Guillevin, Loïc and French Vasculitis Study Grp and French Vasculitis Study Group
Annals of the rheumatic diseases, ISSN 0003-4967, 08/2018, Volume 77, Issue 8, pp. 1143 - 1150
granulomatosis with polyangiitis | ANCA vasculitis | ANCA | CD19+ B lymphocytes | microscopic polyangiitis | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Recurrence | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Drug Monitoring - methods | Rituximab - therapeutic use | Antirheumatic Agents - adverse effects | Adult | Female | Remission Induction - methods | Antirheumatic Agents - therapeutic use | Rituximab - adverse effects | Severity of Illness Index | B-Lymphocyte Subsets - drug effects | Drug Administration Schedule | Kaplan-Meier Estimate | Biomarkers - blood | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Rituximab - administration & dosage | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology | Lymphocyte Count | Aged | Infusions, Intravenous | Precision Medicine - methods | Antibodies, Antineutrophil Cytoplasmic - blood | CD19 antigen | Granulomatosis | Rituximab | Arthritis | Patients | Studies | Cyclophosphamide | Vasculitis | Dyspnea | Lymphocytes B | Medical prognosis | Antineutrophil cytoplasmic antibodies | Remission | Methotrexate | Cytoplasm | Life Sciences | Human health and pathology | Rhumatology and musculoskeletal system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
by de Vos, S and Swinnen, L J and Wang, D and Reid, E and Fowler, N and Cordero, J and Dunbar, M and Enschede, S H and Nolan, C and Petrich, A M and Ross, J A and Salem, A H and Verdugo, M and Agarwal, S and Zhou, L and Kozloff, M and Nastoupil, L J and Flowers, C R
Annals of oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | Salvage Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Rituximab - pharmacokinetics | Bendamustine Hydrochloride - adverse effects | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Bendamustine Hydrochloride - pharmacokinetics | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Rituximab - adverse effects | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Drug Administration Schedule | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Disease Progression | Sulfonamides - pharmacokinetics | Rituximab - administration & dosage | Maximum Tolerated Dose | Progression-Free Survival | Sulfonamides - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Salvage Therapy - methods | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | Index Medicus | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
by Pfreundschuh, Michael and Murawski, Niels and Zeynalova, Samira and Ziepert, Marita and Loeffler, M and Hänel, Matthias and Dierlamm, Judith and Keller, Ulrich and Dreyling, Martin and Truemper, Lorenz and Frickhofen, Norbert and Hünerlitürkoglu, Ali‐Nuri and Schmitz, Norbert and Pöschel, Viola and Rixecker, Tanja and Berdel, Christian and Rübe, Christian and Held, Gerhard and Zwick, Carsten
British journal of haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 3, pp. 410 - 420
diffuse large B‐cell lymphoma | rituximab dose | sex | rituximab pharmacokinetics | diffuse large B-cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - blood | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Antineoplastic Combined Chemotherapy Protocols - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Rituximab - blood | Vincristine - blood | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Aged, 80 and over | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Rituximab - adverse effects | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Treatment Outcome | Prednisone - blood | Rituximab - administration & dosage | Cyclophosphamide - blood | Medication Adherence | Lymphoma, Large B-Cell, Diffuse - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Aged patients | Care and treatment | Anthracyclines | Lymphomas | Corticosteroids | Analysis | Drugs | Toxicity | Sex | Males | Doxorubicin | Optimization | Risk factors | Older people | Rituximab | Pharmacology | Prednisone | Risk analysis | Survival | Patients | Vincristine | Lymphoma | Serum levels | Cyclophosphamide | Lymphocytes B | Medical prognosis | Females | Pharmacokinetics | Geriatrics | B-cell lymphoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights